New Frontiers in Locally Advanced Cervical Cancer Treatment
Journal of Clinical Medicine · 30.07.2024 · 13 (15) · 4458
DOI: 10.3390/jcm13154458 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.07.2024. Verfasst von Roberta Massobrio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Academic Division of Gynecology and Obstetrics, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite the introduction of targeted vaccines and screening protocols, locally advanced cervical cancer represents a median proportion of 37% among all cervical carcinomas. Compared to early stages, it presents significantly lower cure rates, with a 5-year disease-free survival rate of 68% and a 5-year overall survival rate of 74%. According to current guidelines, definitive radiotherapy with concomitant chemotherapy represents the gold standard for locally advanced cervical cancer treatment. However, a significant number of patients relapse and die from metastatic disease. The aim of this narrative review is to examine the recent advancements in treating locally advanced cervical cancer, exploring new frontiers in therapeutic approaches. The PubMed database and clinical trial registries were searched to identify relevant articles published on locally advanced cervical cancer treatment up to March 2024, mainly focusing on papers published in the last decade. Abstracts presented at major international congresses that bring relevant evidence were included. Progress achieved in refining radiotherapy techniques, recent evidence regarding neoadjuvant treatment preceding surgery or concurrent chemoradiotherapy, and key findings concerning adjuvant treatment are thoroughly explored. Furthermore, a comprehensive review of prominent phase II and phase III trials examining the integration of immune checkpoint inhibitors is conducted, analyzing the various contexts in which they are applied. In light of the new evidence that has emerged in recent years and is discussed in this article, the appropriate selection of the most suitable therapeutic approach for each patient remains a complex but crucial issue.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academic Division of Gynecology and Obstetrics, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.
- Department of Radiation Oncology, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.
- Department of Surgical Sciences, University of Turin, 10124 Turin, Italy.
ORCID-Profile: Roberta Massobrio, Daniela Attianese, Annamaria Ferrero
Zitieren
APA
Massobrio, R., Bianco, L., Campigotto, B., Attianese, D., Maisto, E., Pascotto, M., Ruo Redda, M. G., & Ferrero, A. (2024). New Frontiers in Locally Advanced Cervical Cancer Treatment. Journal of Clinical Medicine, 13(15), 4458. https://doi.org/10.3390/jcm13154458
Vancouver
Massobrio R, Bianco L, Campigotto B, Attianese D, Maisto E, Pascotto M, et al. New Frontiers in Locally Advanced Cervical Cancer Treatment. Journal of Clinical Medicine. 2024;13(15):4458. doi:10.3390/jcm13154458
BibTeX
@article{Massobrio2024,
author = {Massobrio, Roberta and Bianco, Lavinia and Campigotto, Beatrice and Attianese, Daniela and Maisto, Elisa and Pascotto, Maria and Ruo Redda, Maria Grazia and Ferrero, Annamaria},
title = {New Frontiers in Locally Advanced Cervical Cancer Treatment},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {15},
pages = {4458},
doi = {10.3390/jcm13154458}
}
EUVIMED